×
German court rules Google must pay €572M for violating antitrust rules in price comparison sector | TechCrunch

German court rules Google must pay €572M for violating antitrust rules in price comparison sector | TechCrunch

A German court has found that Google has abused its dominant market position in the price comparison sector and ruled that the company must pay a total of €572 million ($665.6 million) in damages to two German price comparison companies, according to a report by Reuters.

Google must pay the price comparison platform Idealo about €465 million (about $540 million) in damages, and €107 million (about $124 million) to Producto, another price comparison tool, the report said.

Idealo had claimed damages of €3.3 billion from Google, arguing that its lawsuit was a direct response to the European Court of Justice’s ruling in 2024 that found the search giant was self-preferencing its own shopping comparison service, breaking competition rules, and fined it about $2.7 billion.

Idealo said on Friday that it intends to continue its case against Google and seek the full damages it had sued for.

“We welcome the court of Google holding accountable. But the consequences of self-favoring go far beyond the amount awarded. We will continue to fight – because market abuse must have consequences and must not become a lucrative business model that is worthwhile despite fines and compensation payments,” Idealo’s co-founder and CEO Albrecht von Sonntag said in a statement.

Google said it intends to appeal both rulings. “The changes we made in 2017 are working well, with no intervention from the European Commission. The number of price comparison sites in Europe using the remedy Shopping Unit has multiplied from seven then to 1,550 today,” a Google spokesperson said in an emailed statement.

The company added that it offers rival comparison shopping services the same opportunity as Google Shopping to display ads, and said Google Shopping operates as if it were a separate business, participating in auctions the same as everyone else.

The ruling follows close on the heels of an EU investigation into how Google’s spam policy affects publishers’ search rankings. The company was recently fined €2.95 billion (just under $3.5 billion) by the EU for allegedly breaching EU antitrust rules by favoring its own advertising services.

Note: This story was updated to add a comment from Google.

Source link
#German #court #rules #Google #pay #572M #violating #antitrust #rules #price #comparison #sector #TechCrunch

confirmed that the Find X9S and Find X9 Ultra will launch in India on May 21. The new flagship smartphones are designed for users who prioritize photography and video creation, featuring upgraded Hasselblad camera setups. Alongside the camera upgrades, both smartphones also include large silicon-carbon batteries and dedicated cooling systems for stable performance.

OPPO Find X9 Ultra and X9S: Specs

OPPO Confirms Find X9s and Find X9 Ultra India Launch Date
	
OPPO has officially confirmed that the Find X9S and Find X9 Ultra will launch in India on May 21. The new flagship smartphones are designed for users who prioritize photography and video creation, featuring upgraded Hasselblad camera setups. Alongside the camera upgrades, both smartphones also include large silicon-carbon batteries and dedicated cooling systems for stable performance.



OPPO Find X9 Ultra and X9S: Specs







OPPO has designed the Find X9S with a slim 7.99mm body while still offering premium camera and video capabilities. The device includes three 50MP cameras tuned with Hasselblad technology for consistent imaging results. It also supports Dolby Vision recording and AI features to enhance photos, videos, and everyday usability.



The Hasselblad Master Camera System is a key highlight of the Find X9 series. The purpose of the system is to ensure that the photos produced have balanced colors, good detail, and a consistent photography experience across all the camera sensors on the phone. Another technology OPPO uses to make their images even better is the LUMO Image Engine, which provides high dynamic range, improved clarity, and lower noise levels.



The OPPO Find X9 Ultra features some powerful video tools that are helpful for movie-makers and content creators. The device can capture videos at 8K/30fps and 4K/120fps speeds using all of its cameras. The company also includes features such as O-Log2 and ACES support for pro editing software, as well as a dedicated LUT.



Furthermore, OPPO is focusing on battery life and thermal management with the Find X9 Ultra. The mobile has a 7050mAh battery and an advanced cooling system designed to meet the rigorous demands of creative tasks.



India Launch Date and Expected Availability



OPPO will officially launch the Find X9S and Find X9 Ultra in India on May 21. The company is expected to reveal pricing and sale details during the event itself. The launch further shows OPPO’s strategy to expand its premium flagship portfolio in the Indian smartphone market.

#OPPO #Confirms #Find #X9s #Find #Ultra #India #Launch #DateOppo

OPPO has designed the Find X9S with a slim 7.99mm body while still offering premium camera and video capabilities. The device includes three 50MP cameras tuned with Hasselblad technology for consistent imaging results. It also supports Dolby Vision recording and AI features to enhance photos, videos, and everyday usability.

The Hasselblad Master Camera System is a key highlight of the Find X9 series. The purpose of the system is to ensure that the photos produced have balanced colors, good detail, and a consistent photography experience across all the camera sensors on the phone. Another technology OPPO uses to make their images even better is the LUMO Image Engine, which provides high dynamic range, improved clarity, and lower noise levels.

The OPPO Find X9 Ultra features some powerful video tools that are helpful for movie-makers and content creators. The device can capture videos at 8K/30fps and 4K/120fps speeds using all of its cameras. The company also includes features such as O-Log2 and ACES support for pro editing software, as well as a dedicated LUT.

Furthermore, OPPO is focusing on battery life and thermal management with the Find X9 Ultra. The mobile has a 7050mAh battery and an advanced cooling system designed to meet the rigorous demands of creative tasks.

India Launch Date and Expected Availability

OPPO will officially launch the Find X9S and Find X9 Ultra in India on May 21. The company is expected to reveal pricing and sale details during the event itself. The launch further shows OPPO’s strategy to expand its premium flagship portfolio in the Indian smartphone market.

#OPPO #Confirms #Find #X9s #Find #Ultra #India #Launch #DateOppo">OPPO Confirms Find X9s and Find X9 Ultra India Launch Date
	
OPPO has officially confirmed that the Find X9S and Find X9 Ultra will launch in India on May 21. The new flagship smartphones are designed for users who prioritize photography and video creation, featuring upgraded Hasselblad camera setups. Alongside the camera upgrades, both smartphones also include large silicon-carbon batteries and dedicated cooling systems for stable performance.



OPPO Find X9 Ultra and X9S: Specs







OPPO has designed the Find X9S with a slim 7.99mm body while still offering premium camera and video capabilities. The device includes three 50MP cameras tuned with Hasselblad technology for consistent imaging results. It also supports Dolby Vision recording and AI features to enhance photos, videos, and everyday usability.



The Hasselblad Master Camera System is a key highlight of the Find X9 series. The purpose of the system is to ensure that the photos produced have balanced colors, good detail, and a consistent photography experience across all the camera sensors on the phone. Another technology OPPO uses to make their images even better is the LUMO Image Engine, which provides high dynamic range, improved clarity, and lower noise levels.



The OPPO Find X9 Ultra features some powerful video tools that are helpful for movie-makers and content creators. The device can capture videos at 8K/30fps and 4K/120fps speeds using all of its cameras. The company also includes features such as O-Log2 and ACES support for pro editing software, as well as a dedicated LUT.



Furthermore, OPPO is focusing on battery life and thermal management with the Find X9 Ultra. The mobile has a 7050mAh battery and an advanced cooling system designed to meet the rigorous demands of creative tasks.



India Launch Date and Expected Availability



OPPO will officially launch the Find X9S and Find X9 Ultra in India on May 21. The company is expected to reveal pricing and sale details during the event itself. The launch further shows OPPO’s strategy to expand its premium flagship portfolio in the Indian smartphone market.

#OPPO #Confirms #Find #X9s #Find #Ultra #India #Launch #DateOppo

that the Find X9S and Find X9 Ultra will launch in India on May 21. The new flagship smartphones are designed for users who prioritize photography and video creation, featuring upgraded Hasselblad camera setups. Alongside the camera upgrades, both smartphones also include large silicon-carbon batteries and dedicated cooling systems for stable performance.

OPPO Find X9 Ultra and X9S: Specs

OPPO Confirms Find X9s and Find X9 Ultra India Launch Date
	
OPPO has officially confirmed that the Find X9S and Find X9 Ultra will launch in India on May 21. The new flagship smartphones are designed for users who prioritize photography and video creation, featuring upgraded Hasselblad camera setups. Alongside the camera upgrades, both smartphones also include large silicon-carbon batteries and dedicated cooling systems for stable performance.



OPPO Find X9 Ultra and X9S: Specs







OPPO has designed the Find X9S with a slim 7.99mm body while still offering premium camera and video capabilities. The device includes three 50MP cameras tuned with Hasselblad technology for consistent imaging results. It also supports Dolby Vision recording and AI features to enhance photos, videos, and everyday usability.



The Hasselblad Master Camera System is a key highlight of the Find X9 series. The purpose of the system is to ensure that the photos produced have balanced colors, good detail, and a consistent photography experience across all the camera sensors on the phone. Another technology OPPO uses to make their images even better is the LUMO Image Engine, which provides high dynamic range, improved clarity, and lower noise levels.



The OPPO Find X9 Ultra features some powerful video tools that are helpful for movie-makers and content creators. The device can capture videos at 8K/30fps and 4K/120fps speeds using all of its cameras. The company also includes features such as O-Log2 and ACES support for pro editing software, as well as a dedicated LUT.



Furthermore, OPPO is focusing on battery life and thermal management with the Find X9 Ultra. The mobile has a 7050mAh battery and an advanced cooling system designed to meet the rigorous demands of creative tasks.



India Launch Date and Expected Availability



OPPO will officially launch the Find X9S and Find X9 Ultra in India on May 21. The company is expected to reveal pricing and sale details during the event itself. The launch further shows OPPO’s strategy to expand its premium flagship portfolio in the Indian smartphone market.

#OPPO #Confirms #Find #X9s #Find #Ultra #India #Launch #DateOppo

OPPO has designed the Find X9S with a slim 7.99mm body while still offering premium camera and video capabilities. The device includes three 50MP cameras tuned with Hasselblad technology for consistent imaging results. It also supports Dolby Vision recording and AI features to enhance photos, videos, and everyday usability.

The Hasselblad Master Camera System is a key highlight of the Find X9 series. The purpose of the system is to ensure that the photos produced have balanced colors, good detail, and a consistent photography experience across all the camera sensors on the phone. Another technology OPPO uses to make their images even better is the LUMO Image Engine, which provides high dynamic range, improved clarity, and lower noise levels.

The OPPO Find X9 Ultra features some powerful video tools that are helpful for movie-makers and content creators. The device can capture videos at 8K/30fps and 4K/120fps speeds using all of its cameras. The company also includes features such as O-Log2 and ACES support for pro editing software, as well as a dedicated LUT.

Furthermore, OPPO is focusing on battery life and thermal management with the Find X9 Ultra. The mobile has a 7050mAh battery and an advanced cooling system designed to meet the rigorous demands of creative tasks.

India Launch Date and Expected Availability

OPPO will officially launch the Find X9S and Find X9 Ultra in India on May 21. The company is expected to reveal pricing and sale details during the event itself. The launch further shows OPPO’s strategy to expand its premium flagship portfolio in the Indian smartphone market.

#OPPO #Confirms #Find #X9s #Find #Ultra #India #Launch #DateOppo">OPPO Confirms Find X9s and Find X9 Ultra India Launch Date

OPPO has officially confirmed that the Find X9S and Find X9 Ultra will launch in India on May 21. The new flagship smartphones are designed for users who prioritize photography and video creation, featuring upgraded Hasselblad camera setups. Alongside the camera upgrades, both smartphones also include large silicon-carbon batteries and dedicated cooling systems for stable performance.

OPPO Find X9 Ultra and X9S: Specs

OPPO Confirms Find X9s and Find X9 Ultra India Launch Date
	
OPPO has officially confirmed that the Find X9S and Find X9 Ultra will launch in India on May 21. The new flagship smartphones are designed for users who prioritize photography and video creation, featuring upgraded Hasselblad camera setups. Alongside the camera upgrades, both smartphones also include large silicon-carbon batteries and dedicated cooling systems for stable performance.



OPPO Find X9 Ultra and X9S: Specs







OPPO has designed the Find X9S with a slim 7.99mm body while still offering premium camera and video capabilities. The device includes three 50MP cameras tuned with Hasselblad technology for consistent imaging results. It also supports Dolby Vision recording and AI features to enhance photos, videos, and everyday usability.



The Hasselblad Master Camera System is a key highlight of the Find X9 series. The purpose of the system is to ensure that the photos produced have balanced colors, good detail, and a consistent photography experience across all the camera sensors on the phone. Another technology OPPO uses to make their images even better is the LUMO Image Engine, which provides high dynamic range, improved clarity, and lower noise levels.



The OPPO Find X9 Ultra features some powerful video tools that are helpful for movie-makers and content creators. The device can capture videos at 8K/30fps and 4K/120fps speeds using all of its cameras. The company also includes features such as O-Log2 and ACES support for pro editing software, as well as a dedicated LUT.



Furthermore, OPPO is focusing on battery life and thermal management with the Find X9 Ultra. The mobile has a 7050mAh battery and an advanced cooling system designed to meet the rigorous demands of creative tasks.



India Launch Date and Expected Availability



OPPO will officially launch the Find X9S and Find X9 Ultra in India on May 21. The company is expected to reveal pricing and sale details during the event itself. The launch further shows OPPO’s strategy to expand its premium flagship portfolio in the Indian smartphone market.

#OPPO #Confirms #Find #X9s #Find #Ultra #India #Launch #DateOppo

OPPO has designed the Find X9S with a slim 7.99mm body while still offering premium camera and video capabilities. The device includes three 50MP cameras tuned with Hasselblad technology for consistent imaging results. It also supports Dolby Vision recording and AI features to enhance photos, videos, and everyday usability.

The Hasselblad Master Camera System is a key highlight of the Find X9 series. The purpose of the system is to ensure that the photos produced have balanced colors, good detail, and a consistent photography experience across all the camera sensors on the phone. Another technology OPPO uses to make their images even better is the LUMO Image Engine, which provides high dynamic range, improved clarity, and lower noise levels.

The OPPO Find X9 Ultra features some powerful video tools that are helpful for movie-makers and content creators. The device can capture videos at 8K/30fps and 4K/120fps speeds using all of its cameras. The company also includes features such as O-Log2 and ACES support for pro editing software, as well as a dedicated LUT.

Furthermore, OPPO is focusing on battery life and thermal management with the Find X9 Ultra. The mobile has a 7050mAh battery and an advanced cooling system designed to meet the rigorous demands of creative tasks.

India Launch Date and Expected Availability

OPPO will officially launch the Find X9S and Find X9 Ultra in India on May 21. The company is expected to reveal pricing and sale details during the event itself. The launch further shows OPPO’s strategy to expand its premium flagship portfolio in the Indian smartphone market.

#OPPO #Confirms #Find #X9s #Find #Ultra #India #Launch #DateOppo
How would you like it if, when stumped or just in need of some help with an unfamiliar situation, your doctor consulted a free, ad-supported AI chatbot? That’s not actually a hypothetical. They probably are doing that, a new report from NBC News says.

It’s called OpenEvidence, and NBC says it was “used by about 65% of U.S. doctors across almost 27 million clinical encounters in April alone.” An earlier Bloomberg report on OpenEvidence from seven months ago said it had signed up 50% of American doctors at the time—so reported growth is rapid.

The OpenEvidence homepage trumpets the bot as “America’s Official Medical Knowledge Platform,” and says healthcare professionals qualify for unlimited free use, but non-doctors can try it for free without creating accounts. It gives long, detailed answers with extensive citations that superficially look—to me, a non-doctor—trustworthy and credible.

NBC interviewed doctors for its story, and apparently pressed them on how often they actually click those links to the sources of information, and “most said they only do so when they get an unexpected result,” NBC’s report says.

While it’s free, OpenEvidence is not a charity. It’s a Miami-headquartered tech unicorn with a billionaire founder named David Nadler, and as of January it boasted a $12 billion valuation. NBC says it’s backed by some of the all stars of Sand Hill Road: Sequoia Capital and Andreessen Horowitz, along with Google Ventures, Thrive Capital, and Nvidia.

And its revenue comes from ads (for now), which NBC says are often for “pharmaceutical and medical device companies.”

I’m not capable of stress testing such a piece of software, but I kicked the tires slightly by asking Claude to generate doctor’s notes that are very bad and irresponsible (I said it was just a movie prop).

Your Doctor Is Most Likely Consulting This Free AI Chatbot, Report Says
                How would you like it if, when stumped or just in need of some help with an unfamiliar situation, your doctor consulted a free, ad-supported AI chatbot? That’s not actually a hypothetical. They probably are doing that, a new report from NBC News says. It’s called OpenEvidence, and NBC says it was “used by about 65% of U.S. doctors across almost 27 million clinical encounters in April alone.” An earlier Bloomberg report on OpenEvidence from seven months ago said it had signed up 50% of American doctors at the time—so reported growth is rapid.

 The OpenEvidence homepage trumpets the bot as “America’s Official Medical Knowledge Platform,” and says healthcare professionals qualify for unlimited free use, but non-doctors can try it for free without creating accounts. It gives long, detailed answers with extensive citations that superficially look—to me, a non-doctor—trustworthy and credible. NBC interviewed doctors for its story, and apparently pressed them on how often they actually click those links to the sources of information, and “most said they only do so when they get an unexpected result,” NBC’s report says.

 While it’s free, OpenEvidence is not a charity. It’s a Miami-headquartered tech unicorn with a billionaire founder named David Nadler, and as of January it boasted a  billion valuation. NBC says it’s backed by some of the all stars of Sand Hill Road: Sequoia Capital and Andreessen Horowitz, along with Google Ventures, Thrive Capital, and Nvidia.

 And its revenue comes from ads (for now), which NBC says are often for “pharmaceutical and medical device companies.” I’m not capable of stress testing such a piece of software, but I kicked the tires slightly by asking Claude to generate doctor’s notes that are very bad and irresponsible (I said it was just a movie prop). ©OpenEvidence When I told OpenEvidence those were my notes and asked it to make sure they were good, thankfully, it confirmed that they were bad, saying in part:

  “This clinical documentation raises serious patient safety concerns. The presentation described contains multiple red flags for subarachnoid hemorrhage (SAH) that appear to have been insufficiently weighted, and the current management plan could result in significant harm.”  So that’s somewhat comforting. On the other hand, according to NBC:  “[…]some healthcare providers were quick to point out that OpenEvidence occasionally flubbed or exaggerated its answers, particularly on rare conditions or in ‘edge’ cases.”  NBC’s report also clocked some worries within the medical community and elsewhere, in particular, a “lack of rigorous scientific studies on the tool’s patient impact,” and signs that OpenEvidence might be stunting the intellectual development of recent med school grads:  “One midcareer doctor in Missouri, who requested anonymity given the limited number of providers in their medical field in the country, said he was already seeing the detrimental effects of OpenEvidence on students’ ability to sort signals from noise. ‘My worry is that when we introduce a new tool, any kind of tool that is doing part of your skills that you had trained up for a while beforehand, you start losing those skills pretty quickly”  At a recent doctor’s appointment, my doctor asked my permission to use an AI tool on their phone (I don’t know if it was OpenEvidence). I didn’t know what to say other than yes. Do I want that for my doctor’s appointment? Not especially. But if my doctor has come to rely on a tool like this, then what am I supposed to do? Take away their crutch?      #Doctor #Consulting #Free #Chatbot #ReportArtificial intelligence,doctors,Medicine
©OpenEvidence

When I told OpenEvidence those were my notes and asked it to make sure they were good, thankfully, it confirmed that they were bad, saying in part:

“This clinical documentation raises serious patient safety concerns. The presentation described contains multiple red flags for subarachnoid hemorrhage (SAH) that appear to have been insufficiently weighted, and the current management plan could result in significant harm.”

So that’s somewhat comforting.

On the other hand, according to NBC:

“[…]some healthcare providers were quick to point out that OpenEvidence occasionally flubbed or exaggerated its answers, particularly on rare conditions or in ‘edge’ cases.”

NBC’s report also clocked some worries within the medical community and elsewhere, in particular, a “lack of rigorous scientific studies on the tool’s patient impact,” and signs that OpenEvidence might be stunting the intellectual development of recent med school grads:

“One midcareer doctor in Missouri, who requested anonymity given the limited number of providers in their medical field in the country, said he was already seeing the detrimental effects of OpenEvidence on students’ ability to sort signals from noise.

‘My worry is that when we introduce a new tool, any kind of tool that is doing part of your skills that you had trained up for a while beforehand, you start losing those skills pretty quickly”

At a recent doctor’s appointment, my doctor asked my permission to use an AI tool on their phone (I don’t know if it was OpenEvidence). I didn’t know what to say other than yes. Do I want that for my doctor’s appointment? Not especially. But if my doctor has come to rely on a tool like this, then what am I supposed to do? Take away their crutch?

#Doctor #Consulting #Free #Chatbot #ReportArtificial intelligence,doctors,Medicine">Your Doctor Is Most Likely Consulting This Free AI Chatbot, Report Says
                How would you like it if, when stumped or just in need of some help with an unfamiliar situation, your doctor consulted a free, ad-supported AI chatbot? That’s not actually a hypothetical. They probably are doing that, a new report from NBC News says. It’s called OpenEvidence, and NBC says it was “used by about 65% of U.S. doctors across almost 27 million clinical encounters in April alone.” An earlier Bloomberg report on OpenEvidence from seven months ago said it had signed up 50% of American doctors at the time—so reported growth is rapid.

 The OpenEvidence homepage trumpets the bot as “America’s Official Medical Knowledge Platform,” and says healthcare professionals qualify for unlimited free use, but non-doctors can try it for free without creating accounts. It gives long, detailed answers with extensive citations that superficially look—to me, a non-doctor—trustworthy and credible. NBC interviewed doctors for its story, and apparently pressed them on how often they actually click those links to the sources of information, and “most said they only do so when they get an unexpected result,” NBC’s report says.

 While it’s free, OpenEvidence is not a charity. It’s a Miami-headquartered tech unicorn with a billionaire founder named David Nadler, and as of January it boasted a  billion valuation. NBC says it’s backed by some of the all stars of Sand Hill Road: Sequoia Capital and Andreessen Horowitz, along with Google Ventures, Thrive Capital, and Nvidia.

 And its revenue comes from ads (for now), which NBC says are often for “pharmaceutical and medical device companies.” I’m not capable of stress testing such a piece of software, but I kicked the tires slightly by asking Claude to generate doctor’s notes that are very bad and irresponsible (I said it was just a movie prop). ©OpenEvidence When I told OpenEvidence those were my notes and asked it to make sure they were good, thankfully, it confirmed that they were bad, saying in part:

  “This clinical documentation raises serious patient safety concerns. The presentation described contains multiple red flags for subarachnoid hemorrhage (SAH) that appear to have been insufficiently weighted, and the current management plan could result in significant harm.”  So that’s somewhat comforting. On the other hand, according to NBC:  “[…]some healthcare providers were quick to point out that OpenEvidence occasionally flubbed or exaggerated its answers, particularly on rare conditions or in ‘edge’ cases.”  NBC’s report also clocked some worries within the medical community and elsewhere, in particular, a “lack of rigorous scientific studies on the tool’s patient impact,” and signs that OpenEvidence might be stunting the intellectual development of recent med school grads:  “One midcareer doctor in Missouri, who requested anonymity given the limited number of providers in their medical field in the country, said he was already seeing the detrimental effects of OpenEvidence on students’ ability to sort signals from noise. ‘My worry is that when we introduce a new tool, any kind of tool that is doing part of your skills that you had trained up for a while beforehand, you start losing those skills pretty quickly”  At a recent doctor’s appointment, my doctor asked my permission to use an AI tool on their phone (I don’t know if it was OpenEvidence). I didn’t know what to say other than yes. Do I want that for my doctor’s appointment? Not especially. But if my doctor has come to rely on a tool like this, then what am I supposed to do? Take away their crutch?      #Doctor #Consulting #Free #Chatbot #ReportArtificial intelligence,doctors,Medicine

a new report from NBC News says.

It’s called OpenEvidence, and NBC says it was “used by about 65% of U.S. doctors across almost 27 million clinical encounters in April alone.” An earlier Bloomberg report on OpenEvidence from seven months ago said it had signed up 50% of American doctors at the time—so reported growth is rapid.

The OpenEvidence homepage trumpets the bot as “America’s Official Medical Knowledge Platform,” and says healthcare professionals qualify for unlimited free use, but non-doctors can try it for free without creating accounts. It gives long, detailed answers with extensive citations that superficially look—to me, a non-doctor—trustworthy and credible.

NBC interviewed doctors for its story, and apparently pressed them on how often they actually click those links to the sources of information, and “most said they only do so when they get an unexpected result,” NBC’s report says.

While it’s free, OpenEvidence is not a charity. It’s a Miami-headquartered tech unicorn with a billionaire founder named David Nadler, and as of January it boasted a $12 billion valuation. NBC says it’s backed by some of the all stars of Sand Hill Road: Sequoia Capital and Andreessen Horowitz, along with Google Ventures, Thrive Capital, and Nvidia.

And its revenue comes from ads (for now), which NBC says are often for “pharmaceutical and medical device companies.”

I’m not capable of stress testing such a piece of software, but I kicked the tires slightly by asking Claude to generate doctor’s notes that are very bad and irresponsible (I said it was just a movie prop).

Your Doctor Is Most Likely Consulting This Free AI Chatbot, Report Says
                How would you like it if, when stumped or just in need of some help with an unfamiliar situation, your doctor consulted a free, ad-supported AI chatbot? That’s not actually a hypothetical. They probably are doing that, a new report from NBC News says. It’s called OpenEvidence, and NBC says it was “used by about 65% of U.S. doctors across almost 27 million clinical encounters in April alone.” An earlier Bloomberg report on OpenEvidence from seven months ago said it had signed up 50% of American doctors at the time—so reported growth is rapid.

 The OpenEvidence homepage trumpets the bot as “America’s Official Medical Knowledge Platform,” and says healthcare professionals qualify for unlimited free use, but non-doctors can try it for free without creating accounts. It gives long, detailed answers with extensive citations that superficially look—to me, a non-doctor—trustworthy and credible. NBC interviewed doctors for its story, and apparently pressed them on how often they actually click those links to the sources of information, and “most said they only do so when they get an unexpected result,” NBC’s report says.

 While it’s free, OpenEvidence is not a charity. It’s a Miami-headquartered tech unicorn with a billionaire founder named David Nadler, and as of January it boasted a  billion valuation. NBC says it’s backed by some of the all stars of Sand Hill Road: Sequoia Capital and Andreessen Horowitz, along with Google Ventures, Thrive Capital, and Nvidia.

 And its revenue comes from ads (for now), which NBC says are often for “pharmaceutical and medical device companies.” I’m not capable of stress testing such a piece of software, but I kicked the tires slightly by asking Claude to generate doctor’s notes that are very bad and irresponsible (I said it was just a movie prop). ©OpenEvidence When I told OpenEvidence those were my notes and asked it to make sure they were good, thankfully, it confirmed that they were bad, saying in part:

  “This clinical documentation raises serious patient safety concerns. The presentation described contains multiple red flags for subarachnoid hemorrhage (SAH) that appear to have been insufficiently weighted, and the current management plan could result in significant harm.”  So that’s somewhat comforting. On the other hand, according to NBC:  “[…]some healthcare providers were quick to point out that OpenEvidence occasionally flubbed or exaggerated its answers, particularly on rare conditions or in ‘edge’ cases.”  NBC’s report also clocked some worries within the medical community and elsewhere, in particular, a “lack of rigorous scientific studies on the tool’s patient impact,” and signs that OpenEvidence might be stunting the intellectual development of recent med school grads:  “One midcareer doctor in Missouri, who requested anonymity given the limited number of providers in their medical field in the country, said he was already seeing the detrimental effects of OpenEvidence on students’ ability to sort signals from noise. ‘My worry is that when we introduce a new tool, any kind of tool that is doing part of your skills that you had trained up for a while beforehand, you start losing those skills pretty quickly”  At a recent doctor’s appointment, my doctor asked my permission to use an AI tool on their phone (I don’t know if it was OpenEvidence). I didn’t know what to say other than yes. Do I want that for my doctor’s appointment? Not especially. But if my doctor has come to rely on a tool like this, then what am I supposed to do? Take away their crutch?      #Doctor #Consulting #Free #Chatbot #ReportArtificial intelligence,doctors,Medicine
©OpenEvidence

When I told OpenEvidence those were my notes and asked it to make sure they were good, thankfully, it confirmed that they were bad, saying in part:

“This clinical documentation raises serious patient safety concerns. The presentation described contains multiple red flags for subarachnoid hemorrhage (SAH) that appear to have been insufficiently weighted, and the current management plan could result in significant harm.”

So that’s somewhat comforting.

On the other hand, according to NBC:

“[…]some healthcare providers were quick to point out that OpenEvidence occasionally flubbed or exaggerated its answers, particularly on rare conditions or in ‘edge’ cases.”

NBC’s report also clocked some worries within the medical community and elsewhere, in particular, a “lack of rigorous scientific studies on the tool’s patient impact,” and signs that OpenEvidence might be stunting the intellectual development of recent med school grads:

“One midcareer doctor in Missouri, who requested anonymity given the limited number of providers in their medical field in the country, said he was already seeing the detrimental effects of OpenEvidence on students’ ability to sort signals from noise.

‘My worry is that when we introduce a new tool, any kind of tool that is doing part of your skills that you had trained up for a while beforehand, you start losing those skills pretty quickly”

At a recent doctor’s appointment, my doctor asked my permission to use an AI tool on their phone (I don’t know if it was OpenEvidence). I didn’t know what to say other than yes. Do I want that for my doctor’s appointment? Not especially. But if my doctor has come to rely on a tool like this, then what am I supposed to do? Take away their crutch?

#Doctor #Consulting #Free #Chatbot #ReportArtificial intelligence,doctors,Medicine">Your Doctor Is Most Likely Consulting This Free AI Chatbot, Report Says

How would you like it if, when stumped or just in need of some help with an unfamiliar situation, your doctor consulted a free, ad-supported AI chatbot? That’s not actually a hypothetical. They probably are doing that, a new report from NBC News says.

It’s called OpenEvidence, and NBC says it was “used by about 65% of U.S. doctors across almost 27 million clinical encounters in April alone.” An earlier Bloomberg report on OpenEvidence from seven months ago said it had signed up 50% of American doctors at the time—so reported growth is rapid.

The OpenEvidence homepage trumpets the bot as “America’s Official Medical Knowledge Platform,” and says healthcare professionals qualify for unlimited free use, but non-doctors can try it for free without creating accounts. It gives long, detailed answers with extensive citations that superficially look—to me, a non-doctor—trustworthy and credible.

NBC interviewed doctors for its story, and apparently pressed them on how often they actually click those links to the sources of information, and “most said they only do so when they get an unexpected result,” NBC’s report says.

While it’s free, OpenEvidence is not a charity. It’s a Miami-headquartered tech unicorn with a billionaire founder named David Nadler, and as of January it boasted a $12 billion valuation. NBC says it’s backed by some of the all stars of Sand Hill Road: Sequoia Capital and Andreessen Horowitz, along with Google Ventures, Thrive Capital, and Nvidia.

And its revenue comes from ads (for now), which NBC says are often for “pharmaceutical and medical device companies.”

I’m not capable of stress testing such a piece of software, but I kicked the tires slightly by asking Claude to generate doctor’s notes that are very bad and irresponsible (I said it was just a movie prop).

Your Doctor Is Most Likely Consulting This Free AI Chatbot, Report Says
                How would you like it if, when stumped or just in need of some help with an unfamiliar situation, your doctor consulted a free, ad-supported AI chatbot? That’s not actually a hypothetical. They probably are doing that, a new report from NBC News says. It’s called OpenEvidence, and NBC says it was “used by about 65% of U.S. doctors across almost 27 million clinical encounters in April alone.” An earlier Bloomberg report on OpenEvidence from seven months ago said it had signed up 50% of American doctors at the time—so reported growth is rapid.

 The OpenEvidence homepage trumpets the bot as “America’s Official Medical Knowledge Platform,” and says healthcare professionals qualify for unlimited free use, but non-doctors can try it for free without creating accounts. It gives long, detailed answers with extensive citations that superficially look—to me, a non-doctor—trustworthy and credible. NBC interviewed doctors for its story, and apparently pressed them on how often they actually click those links to the sources of information, and “most said they only do so when they get an unexpected result,” NBC’s report says.

 While it’s free, OpenEvidence is not a charity. It’s a Miami-headquartered tech unicorn with a billionaire founder named David Nadler, and as of January it boasted a  billion valuation. NBC says it’s backed by some of the all stars of Sand Hill Road: Sequoia Capital and Andreessen Horowitz, along with Google Ventures, Thrive Capital, and Nvidia.

 And its revenue comes from ads (for now), which NBC says are often for “pharmaceutical and medical device companies.” I’m not capable of stress testing such a piece of software, but I kicked the tires slightly by asking Claude to generate doctor’s notes that are very bad and irresponsible (I said it was just a movie prop). ©OpenEvidence When I told OpenEvidence those were my notes and asked it to make sure they were good, thankfully, it confirmed that they were bad, saying in part:

  “This clinical documentation raises serious patient safety concerns. The presentation described contains multiple red flags for subarachnoid hemorrhage (SAH) that appear to have been insufficiently weighted, and the current management plan could result in significant harm.”  So that’s somewhat comforting. On the other hand, according to NBC:  “[…]some healthcare providers were quick to point out that OpenEvidence occasionally flubbed or exaggerated its answers, particularly on rare conditions or in ‘edge’ cases.”  NBC’s report also clocked some worries within the medical community and elsewhere, in particular, a “lack of rigorous scientific studies on the tool’s patient impact,” and signs that OpenEvidence might be stunting the intellectual development of recent med school grads:  “One midcareer doctor in Missouri, who requested anonymity given the limited number of providers in their medical field in the country, said he was already seeing the detrimental effects of OpenEvidence on students’ ability to sort signals from noise. ‘My worry is that when we introduce a new tool, any kind of tool that is doing part of your skills that you had trained up for a while beforehand, you start losing those skills pretty quickly”  At a recent doctor’s appointment, my doctor asked my permission to use an AI tool on their phone (I don’t know if it was OpenEvidence). I didn’t know what to say other than yes. Do I want that for my doctor’s appointment? Not especially. But if my doctor has come to rely on a tool like this, then what am I supposed to do? Take away their crutch?      #Doctor #Consulting #Free #Chatbot #ReportArtificial intelligence,doctors,Medicine
©OpenEvidence

When I told OpenEvidence those were my notes and asked it to make sure they were good, thankfully, it confirmed that they were bad, saying in part:

“This clinical documentation raises serious patient safety concerns. The presentation described contains multiple red flags for subarachnoid hemorrhage (SAH) that appear to have been insufficiently weighted, and the current management plan could result in significant harm.”

So that’s somewhat comforting.

On the other hand, according to NBC:

“[…]some healthcare providers were quick to point out that OpenEvidence occasionally flubbed or exaggerated its answers, particularly on rare conditions or in ‘edge’ cases.”

NBC’s report also clocked some worries within the medical community and elsewhere, in particular, a “lack of rigorous scientific studies on the tool’s patient impact,” and signs that OpenEvidence might be stunting the intellectual development of recent med school grads:

“One midcareer doctor in Missouri, who requested anonymity given the limited number of providers in their medical field in the country, said he was already seeing the detrimental effects of OpenEvidence on students’ ability to sort signals from noise.

‘My worry is that when we introduce a new tool, any kind of tool that is doing part of your skills that you had trained up for a while beforehand, you start losing those skills pretty quickly”

At a recent doctor’s appointment, my doctor asked my permission to use an AI tool on their phone (I don’t know if it was OpenEvidence). I didn’t know what to say other than yes. Do I want that for my doctor’s appointment? Not especially. But if my doctor has come to rely on a tool like this, then what am I supposed to do? Take away their crutch?

#Doctor #Consulting #Free #Chatbot #ReportArtificial intelligence,doctors,Medicine

Post Comment